CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
NextGeneTx aims to enhance gene therapy using adeno-associated virus vectors by addressing the limitations of current methods. The project focuses on improving the efficiency of protein reconstitution and reducing by-products, with applications in treating retinal diseases.
Despite 6 products on the market and dozens in advanced phases of clinical development, in vivo gene therapy with vectors derived from adeno-associated viruses (AAV) still faces the major challenge of the limited vector cargo capacity (< 5kb).
This prevents AAV application for treatment of inherited diseases caused by mutations in large genes.
To address this, we have recently developed an AAV-based strategy relying on the use of short protein elements called inteins.
These, when fused at the ex…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Pozzuoli
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
NEXT GENERATION DIAGNOSTIC SRL
Italy, Pozzuoli
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
